Presentation is loading. Please wait.

Presentation is loading. Please wait.

Research Strategies to Test Behavioral/Psychotherapy Treatments for Substance Use Disorders: Several Examples Richard A. Rawson, Ph.D UCLA ISAP Cairo,

Published byHannah Cole Modified over 9 years ago

Similar presentations

Presentation on theme: "Research Strategies to Test Behavioral/Psychotherapy Treatments for Substance Use Disorders: Several Examples Richard A. Rawson, Ph.D UCLA ISAP Cairo,"— Presentation transcript:

1 Research Strategies to Test Behavioral/Psychotherapy Treatments for Substance Use Disorders: Several Examples Richard A. Rawson, Ph.D UCLA ISAP Cairo, Egypt Sept 27, 2004

2 Research on Behavioral/Psychotherapy Treatments: Considerations Many of the research design principles described for medication research apply We want to compare our experimental treatment with a standardized comparison condition. The comparison condition has to be minimal, but defensible from an ethical point of view.

3 Research on Behavioral/Psychotherapy Treatments: Considerations Except, with behavioral/psychotherapy: “Double-blind, placebo controlled trials not possible. “No treatment control groups” not ethical Major strategy is to compare different active treatments, or different “doses” of a therapy.

4 Research on Behavioral/Psychotherapy Treatments: Considerations Possible comparison groups Waiting list control Smaller (minimal) dose “Treatment as usual” Adding experimental treatment as an added piece of treatment on top of a standard treatment received by everyone in both groups Some control activity requiring the same amount of time, which is defensible as a clinical intervention (eg. bibliotherapy, viewing educational videotapes.

5 Research on Behavioral/Psychotherapy Treatments: Considerations Fidelity measures are critical (are they getting the therapy we want to test) Specific therapist effects How much of the “dose” do they actually receive? (as opposed to what they receive ideally)

6 Elements in a successful behavioral/psychotherapy treatment outcome study report Describe intervention(s) clearly Describe study population Describe fidelity and dose delivered information Describe analysis of major outcome during the treatment period Describe analysis of intervention effect post- treatment Describe relationship of subject characteristics and outcomes Describe relationship of treatment “dose” and outcomes Others

7 A Multi-Site Comparison of Psychosocial Approaches for the Treatment of Methamphetamine Dependence Richard A. Rawson, Ph.D. and The Methamphetamine Treatment Project Corporate Authors* Addiction (2004, June)

8 Project Goals: To study the clinical effectiveness of the Matrix Model To compare the effectiveness of the Matrix model to other locally available outpatient treatments To establish the cost and cost effectiveness of the Matrix model compared to other outpatient treatments To explore the replicability of the Matrix model and challenges involved in technology transfer

9 CSAT MTP Study Treatment as Usual Varied length Varied frequency Varied type Variable training No fidelity measures Matrix Model 3 visits per week 16 weeks long Content Standardized Training Standardized Fidelity to protocol insured

10 Sample Description

11 Baseline Demographics Participants Served (n)1016 Age (mean)32.8 years Education (mean)12.2 years Methamphetamine Use (mean)7.5 years Marijuana Use (mean)7.2 years Alcohol Use (mean)7.6 years

12 Gender Distribution of Participants

13 Ethnic Identification of Participants

14 Marital Status of Participants

15 Employment Status of Participants

16 Route of Methamphetamine Administration

17 Changes from Baseline to Treatment-end

18 Days Paid for Work in Past 30 Possible is 0-30; t paired =6.01; p-value<0.000 (highly sig.)

19 Total Income (Past 30 days) of Participants t paired =2.34; p-value=0.02 (sig.)

20 ASI Composite Scores Possible is 0-1; Higher : worse problem t paired : *p-value<0.03 (sig.), **p-value<0.000 (highly sig.)

21 Days of Methamphetamine Use in Past 30 (ASI) Possible is 0-30; t paired =20.90; p-value<0.000 (highly sig.)

22 Days of Marijuana Use in Past 30 (ASI) Possible is 0-30; t paired =8.02; p-value<0.000 (highly sig.)

23 Days of Alcohol Use in Past 30 (ASI) Possible is 0-30; t paired =6.47; p-value<0.000 (highly sig.)

24 Beck Depression Inventory (BDI) Total Scores Possible is 0-63; t paired =16.87; p-value<0.000 (highly sig.)

25 BSI Scores (mean) BL 1 Tx-end Paired t * Somatization0.70.57.67 Obsessive-Compulsive1.20.911.40 Interpersonal Sensitivity1.00.711.40 Depression1.20.811.98 Anxiety0.90.611.24 Hostility0.80.69.39 Phobic Anxiety0.60.48.47 Paranoid Ideation1.10.711.49 Psychoticism0.90.610.70 1 Possible, all scores, is 0-4; * all p-values<0.000 (highly sig.)

26 Positive Symptom Total (PST) from Brief Symptom Inventory (BSI) Possible is 0-53; t paired =14.33; p-value<0.000 (highly sig.)

27 Site (TAU length, wks.) TAU Mean SD Matrix 16-week Mean SD Site 1 (8) 17.225.2 Site 2 (12) 21.726.1 Site 3 (12) 6.328.4 Site 4 (16) 22.831.5 Site 5 (12) 15.425.7 Site 6 (12) 2.125.2 Site 7 (16) 13.835.4 Site 8 (12) 3.922.2 Overall summary 12.726.8 Table 5. Summary of the number of clinical contacts made by participants, by treatment group and site

28 Figure 3. Participant retention throughout treatment, by site and treatment group

29 Site TAU length (wks.) Log-rank Chi-square p Site 1 8 -20.07 33.17 <0.0001 Site 212 -9.49 4.980.026 Site 312 -8.39 3.680.055 Site 416 1.64 0.260.610 Site 512 -22.30 28.74<0.0001 Site 612 -17.46 17.87<0.0001 Site 716 -5.01 3.340.067 Site 812 -10.59 7.990.005 Table 7. Comparison of retention between groups within sites, with Matrix truncated to the length of TAU at each site

30 Figure 4. Percent completing treatment, by group

31 Figure 5. Mean number of MA-free urine samples, by treatment length and treatment group (Matrix group data truncated to the length of TAU)

32 Site (TAU length, wks.) Raw DataTruncated Data Matrix16TAUMatrix16TAU tp meanSDmeanSDmeanSDmeanSD Site 1 (8) 6.233.38 3.753.38 -0.760.45 Site 2 (12) 6.254.19 4.864.19 -0.940.35 Site 3 (12) 5.753.62 4.613.62 -1.520.13 Site 4 (16) 8.448.6 8.448.6 0.130.89 Site 5 (12) 5.191.72 4.301.72 -3.700.0003 Site 6 (12) 4.243.27 3.33.27 -0.040.97 Site 7 (16) 7.04.54 7.04.54 -1.500.14 Site 8 (12) 5.393.30 4.283.30 -1.230.22 Table 8. Summary of the number of MA-free urine samples provided by participants, by treatment group and site

33 Site (TAU length, wks.) Raw DataTruncated Data Matrix16TAUMatrix16TAU tp meanSDmeanSDmeanSDmeanSD Site 1 (8) 3.5752.7542.8772.754 - 0.9820.328 Site 2 (12) 3.7532.4743.3772.474-1.470.144 Site 3 (12) 3.1971.8053.0131.805-2.160.033 Site 4 (16) 6.1405.5606.1405.560 - 0.5460.586 Site 5 (12) 3.8891.2793.4291.279 - 3.3930.001 Site 6 (12) 2.4292.3422.3142.3420.20.841 Site 7 (16) 4.6822.5424.6822.542 - 1.5860.121 Site 8 (12) 2.8332.1302.5192.130 - 0.5510.583 Table 9. Longest MA abstinent period by treatment group and site

34 Figure 2. Mean number of weekly data visits attended, by treatment length and treatment group (Matrix group data truncated to the length of TAU)

35 Discharge UA Result by Attendance During Treatment and Group Matrix 16TAU cleanmissingdirty

36 Figure 1. Overall participant follow-up by treatment condition and time point

37 6-mos. F.U. UA Result by Attendance During Treatment and Group Matrix 16 TAU MA-missingMA+

38 Figure 5. Urinalysis Results: %Meth Negative

39 Figure 6. Participant self-report of MA use (number of days during the past 30) at enrollment, discharge, and 6-month follow-up, by treatment condition

40 MTP Study Conclusions A multisite evaluation of a research-based intervention can be conducted in community sites during a 3 year period. Six research-naïve sites and 2 experienced sites successfully were trained and conducted all necessary research activities for a complex clinical trial. A complex psychosocial treatment protocol was successfully replicated at 8 sites over a 3 year period. Over 1000 MA-Users received free treatment.

41 MTP Study Conclusions Treatment for MA dependence associated with improvements in many domains including drug use, mj use, mood, Income Matrix treatment results in longer retention, more sessions attended, more treatment completers, more MA-negative Uas, longer periods of MA abstinence * Except for drug court site

42 MTP Study Conclusions Outcomes at discharge and follow-up demonstrated comparable results between Matrix and TAU Program compliance associated with superior urinalysis results at discharge and follow-up

43 MTP Study Conclusions The design of multi-site studies has to carefully consider priorities among the following issues: Priority of testing the null hypothesis of the primary study outcomes Flexibility to accommodate all investigators individual site priorities and site program variability

44 Site Duration of Treatment Intensive Phase Individual Sessions Group Sessions 12-Step Program Involvement Site 1 8 wks 1x/wk x 4-8 wks, 30-50 min each 4x/wk x 4-8 wks, 3hr each, families attend 1x/wk required; 1x/wk x 4-8 wks Site 2 12 wks 1x/wk x 12 wks, 1 hr each 5x/wk x 2wk, 3x/wk x 2wks, 2x/wk x 8 wks recommended Site 3 12 wks 1x/wk x 12 wks, 1 hr each nonerecommended Site 4 16 wks 1x/wk x 16 wks, 10-15 min each 3x/wk x 16 wks, 1 hr each required; 3x/wk x 16 wks Site 5 12 wks 1x/wk x 12 wks, 30-60 min each 3x/wk x 12 wks, 90 min each and 2x/wk x 12 wks, 60- 90 min each required; 1x/wk x 12 wks Site 6 12 wks 1x/wk – 2x/mo x 12 wks, 1 hr each 2x/wk x 12 wks, 90 min each, families attend 1x/2 wks recommended Site 7 16 wks 1x/wk x 16 wks, 1 hr each 2x/wk x 16 wks, 2 hrs each recommended Site 8 12 wks 2x/wk x 12 wks, 1 hr each 1x/wk x 12 wks, 2 hrs each required; 6 meetings Table 2. Treatment-As-Usual: Elements of Treatment

45 Site TAU (n) Matrix 16-week (n) Total Site 1 69 73 142 Site 27877155 Site 37776153 Site 45057107 Site 56163124 Site 67370143 Site 7242246 Site 854 108 Overall TOTAL486492978 Table 3. Enrollment in the MTP by Site and Treatment Condition

46 CharacteristicSummary % Male45 Age (Yrs.), mean (sd)32.8 (8.0) Ethnicity (%) Caucasian60 African-American2 American Indian3 Asian/Pacific Islander17 Hispanic18 Educational Attainment Level (yrs.), mean (sd)12.2 (1.7) % Employed69 % Married (and not separated)16 Overall Substance Use Patterns-Lifetime (yrs.), mean (sd) Methamphetamine7.54 (6) Alcohol7.6 (8.5) Cocaine1.75 (3.5) Cannabis7.15 (8) Overall Substance Use Patterns—Days in Past 30, mean (sd) Methamphetamine11.53 (9.6) Alcohol4.72 (7.3) Cocaine0.21 (1) Cannabis4.38 (8.3) Preferred Route of Administration of MA (%) Oral0 Nasal11 Smoked65 IV- injection24 Table 4. MTP Participant Characteristics (taken from baseline ASI)

47 Site (TAU length, wks.) TAU Mean SD Matrix 16-week Mean SD Site 1 (8) 17.214.025.217.9 Site 2 (12) 21.715.726.117.3 Site 3 (12) 6.33.628.418.2 Site 4 (16) 22.815.431.520.0 Site 5 (12) 15.419.825.720.0 Site 6 (12) 2.13.125.224.7 Site 7 (16) 13.814.535.419.1 Site 8 (12) 3.95.022.218.6 Overall summary 12.714.726.819.7 Table 5. Summary of the number of clinical contacts made by participants, by treatment group and site

48 Site TAU length (wks.) Log-rank Chi-square p Site 1 8 -20.07 33.17 <0.0001 Site 212 -9.49 4.980.026 Site 312 -8.39 3.680.055 Site 416 1.64 0.260.610 Site 512 -22.30 28.74<0.0001 Site 612 -17.46 17.87<0.0001 Site 716 -5.01 3.340.067 Site 812 -10.59 7.990.005 Table 7. Comparison of retention between groups within sites, with Matrix truncated to the length of TAU at each site

49 Site (TAU length, wks.) Raw DataTruncated Data Matrix16TAUMatrix16TAU tp meanSDmeanSDmeanSDmeanSD Site 1 (8) 6.235.413.382.95 3.752.913.382.95-0.760.45 Site 2 (12) 6.255.944.194.24 4.864.594.194.24-0.940.35 Site 3 (12) 5.755.513.623.67 4.614.283.623.67-1.520.13 Site 4 (16) 8.446.288.66.18 8.446.288.66.180.130.89 Site 5 (12) 5.195.901.722.88 4.304.651.722.88-3.700.0003 Site 6 (12) 4.245.363.274.12 3.34.193.274.12-0.040.97 Site 7 (16) 7.05.934.545.22 7.05.934.545.22-1.500.14 Site 8 (12) 5.395.653.304.05 4.284.233.304.05-1.230.22 Table 8. Summary of the number of MA-free urine samples provided by participants, by treatment group and site

50 Site (TAU length, wks.) Raw DataTruncated Data Matrix16TAUMatrix16TAU tp meanSDmeanSDmeanSDmeanSD Site 1 (8) 3.5754.6002.7543.1832.8773.1092.7543.183 - 0.9820.328 Site 2 (12) 3.7535.1052.4743.3063.3774.2712.4743.306-1.470.144 Site 3 (12) 3.1974.4841.8052.7633.0134.0281.8052.763-2.160.033 Site 4 (16) 6.1405.7715.5605.2186.1405.7715.5605.218 - 0.5460.586 Site 5 (12) 3.8895.4391.2792.2743.4294.4671.2792.274 - 3.3930.001 Site 6 (12) 2.4293.8432.3423.6712.3143.4912.3423.6710.20.841 Site 7 (16) 4.6825.0562.5423.9784.6825.0562.5423.978 - 1.5860.121 Site 8 (12) 2.8334.7052.1303.4482.5193.8792.1303.448 - 0.5510.583 Table 9. Longest MA abstinent period by treatment group and site

51 Figure 1. Overall participant follow-up by treatment condition and time point

52 Figure 2. Mean number of weekly data visits attended, by treatment length and treatment group (Matrix group data truncated to the length of TAU)

53 Figure 3. Participant retention throughout treatment, by site and treatment group

54 Figure 4. Percent completing treatment, by group

55 Figure 5. Mean number of MA-free urine samples, by treatment length and treatment group (Matrix group data truncated to the length of TAU)

56 Figure 6. Participant self-report of MA use (number of days during the past 30) at enrollment, discharge, and 6-month follow-up, by treatment condition

57

Download ppt "Research Strategies to Test Behavioral/Psychotherapy Treatments for Substance Use Disorders: Several Examples Richard A. Rawson, Ph.D UCLA ISAP Cairo,"

Similar presentations

1 Intervening in the Recovery Process Michael L. Dennis, Ph.D. Christy K Scott, Ph.D. Chestnut Health Systems, Bloomington &Chicago, IL U.S.A. Presentation.

1 Intervening in the Recovery Process Michael L. Dennis, Ph.D. Christy K Scott, Ph.D. Chestnut Health Systems, Bloomington &Chicago, IL U.S.A. Presentation.
What is the evidence for time limiting addiction treatment?

What is the evidence for time limiting addiction treatment?
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.

Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Substance Use: Substance use comparisons included lifetime and past 30 day use (Figure 3) and lifetime use. For past 30 day use, more men reported heroin.

Substance Use: Substance use comparisons included lifetime and past 30 day use (Figure 3) and lifetime use. For past 30 day use, more men reported heroin.
® Introduction Low Back Pain and Physical Function Among Different Ethnicities Adelle A Safo, Sarah Holder DO, Sandra Burge PhD The University of Texas.

® Introduction Low Back Pain and Physical Function Among Different Ethnicities Adelle A Safo, Sarah Holder DO, Sandra Burge PhD The University of Texas.
 More than 2 million men and women have been deployed to Afghanistan and Iraq for Operations Enduring Freedom/Iraqi Freedom (OEF/OIF).  ~21% of men and.

 More than 2 million men and women have been deployed to Afghanistan and Iraq for Operations Enduring Freedom/Iraqi Freedom (OEF/OIF).  ~21% of men and.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.
Motivational Interviewing to Improve Treatment Engagement and Outcome* The effect of one session on retention Research findings from the NIDA Clinical.

Motivational Interviewing to Improve Treatment Engagement and Outcome* The effect of one session on retention Research findings from the NIDA Clinical.
Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.

Challenges and Successes Treating Adolescent Substance Use Disorders Janet L. Brody, Ph.D. Center for Family and Adolescent Research (CFAR), Oregon Research.
Richard Rawson Ph.D. U.C.L.A. Integrated Substance Abuse Programs (I.S.A.P.) The MTP Site Investigators Funded by the Center for Substance Abuse Treatment.

Richard Rawson Ph.D. U.C.L.A. Integrated Substance Abuse Programs (I.S.A.P.) The MTP Site Investigators Funded by the Center for Substance Abuse Treatment.
Treatment of Methamphetamine Dependence: Does Treatment Work? Mary Lynn Brecht, Ph.D. Richard A. Rawson, Ph.D Semel Institute for Neuroscience and Human.

Treatment of Methamphetamine Dependence: Does Treatment Work? Mary Lynn Brecht, Ph.D. Richard A. Rawson, Ph.D Semel Institute for Neuroscience and Human.
MTP Marijuana Treatment Project The Multi-site Study of the Effectiveness of Brief Treatment for Cannabis Dependence A Cooperative Agreement funded by.

MTP Marijuana Treatment Project The Multi-site Study of the Effectiveness of Brief Treatment for Cannabis Dependence A Cooperative Agreement funded by.
® Introduction Mental Health Predictors of Pain and Function in Patients with Chronic Low Back Pain Olivia D. Lara, K. Ashok Kumar MD FRCS Sandra Burge,

® Introduction Mental Health Predictors of Pain and Function in Patients with Chronic Low Back Pain Olivia D. Lara, K. Ashok Kumar MD FRCS Sandra Burge,
® Introduction Low Back Pain Remedies and Procedures: Helpful or Harmful? Lauren Lyons, Terrell Benold, MD, Sandra Burge, PhD The University of Texas Health.

® Introduction Low Back Pain Remedies and Procedures: Helpful or Harmful? Lauren Lyons, Terrell Benold, MD, Sandra Burge, PhD The University of Texas Health.
Enhancing Co-Occurring Disorder Services in Addiction Treatment: Preliminary Findings of the Texas Co-Occurring State Incentive Grant Dartmouth Psychiatric.

Enhancing Co-Occurring Disorder Services in Addiction Treatment: Preliminary Findings of the Texas Co-Occurring State Incentive Grant Dartmouth Psychiatric.
UCLA Integrated Substance Abuse Programs (ISAP). CSAT MTP Project Goals: To study the clinical effectiveness of the Matrix Model To study the clinical.

UCLA Integrated Substance Abuse Programs (ISAP). CSAT MTP Project Goals: To study the clinical effectiveness of the Matrix Model To study the clinical.
Audrey J. Brooks, PhD University of Arizona CA-AZ node.

Audrey J. Brooks, PhD University of Arizona CA-AZ node.
Using Research/Evaluation Questions to Define Data Collection and Findings: Findings from the FY 2004 KTOS Follow-up Study Robert Walker, Allison Mateyoke-Scrivener,

Using Research/Evaluation Questions to Define Data Collection and Findings: Findings from the FY 2004 KTOS Follow-up Study Robert Walker, Allison Mateyoke-Scrivener,
INTENSIVE ACCEPTANCE AND COMMITMENT THERAPY WITH AT- RISK ADOLESCENTS Emily B. Kroska Rosaura Orengo-Aguayo James Marchman.

INTENSIVE ACCEPTANCE AND COMMITMENT THERAPY WITH AT- RISK ADOLESCENTS Emily B. Kroska Rosaura Orengo-Aguayo James Marchman.
Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.

Frequency and type of adverse events associated with treating women with trauma in community substance abuse treatment programs T. KIlleen 1, C. Brown.

Similar presentations

Ads by Google